A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
← catalyst calendarNCT06500702 · readout in 126 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
84estimated
Sites
71
Countries
Argentina, Australia, Brazil +19
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-19 | actual | When the study began enrolling |
| Primary completion | 2026-12-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-02-16 | estimated | The whole study's end, after follow-up |
| First posted | 2024-07-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Focal Segmental Glomerulosclerosis
- Glomerulonephritis Minimal Lesion
Interventions
- Drug: frexalimab
- Drug: brivekimig
- Drug: rilzabrutinib
- Drug: placebo
Primary outcome
what the primary-completion date above is the date OFPercent reduction in urine protein to creatinine ratio (UPCR)
measured From baseline to Week 12
Publications
- PMID 39899371 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed